-
2023-510320-71-00
4
2020-10-27
Squamous cell carcinoma of vulva/vagina
-
2023-505336-34-00
6
2020-10-08
Metastatic solid tumors
-
2024-516670-29-00
4
2020-09-15
Multiple Myeloma
-
2023-506435-15-00
3
2020-08-25
Prostate cancer
-
2023-506313-21-00
9
2020-08-03
PD-1 refractory melanoma
-
2023-506314-51-00
9
2020-07-31
Stage IIIB or IIIC or IIID melanoma
-
2023-506312-41-00
9
2020-07-30
PD-1 refractory melanoma
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2023-505035-12-00
5
2020-06-12
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2024-513984-22-00
4
2020-03-17
Patients with metastatic GIST
-
2023-507904-30-00
3
2020-01-27
solid tumors
-
2023-508364-29-00
5
2019-11-22
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-514873-22-00
5
2019-10-16
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
-
2024-515532-72-00
4
2019-10-08
non small cell lung cancer
-
2022-502858-14-00
5
2019-09-05
Hypertrophic cardiomyopathy
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2023-509053-32-00
5
2019-07-17
Locoregional Hepatocellular Carcinoma (HCC)
-
2023-509848-10-00
5
2019-06-12
Multiple myeloma (MM) with at least 2 prior therapies including an imm
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-501971-24-00
5
2019-05-20
Adjuvant treatment of HCC
-
2023-507777-18-00
4
2019-03-19
Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
-
2023-508207-21-00
9
2019-02-08
Advanced Malignant Tumors
-
2023-508343-48-00
5
2019-01-25
Adult patients with relapsed or refractory aggressive B-cell non-Hodgk